イミュノ・ジェネックスは、がんの根治を目的とするバイオテクノロジー研究機関として設立され、最先端の遺伝子解析や免疫システム研究などの側面から臨床をサポートしてきました。GenomicsやProteomics、Metabolomics、Epigenetics等、バイオテクノロジーの進歩により、昨今の疾患研究や診断技術、治療技術は分子レベルで進展しています。
私たちは、個別化医療の概念に基づくこれからの医療に必要なライフサイエンスのさらなる深化と応用、エビデンスの蓄積を進めています。病気を発症させない先制医療、そして、最適な医療による最速の治療を実現するために、学際的な研究と技術確立を通して、臨床の先生方や患者様に貢献することが私たちの使命です。

At ImmunoGenex our mission is to provide support in the field of personalized and regenerative medicine to give individuals the most advanced, best care in the world.
We are a leading-edge biotechnology company committed to providing an accurate picture of one's health and risk factors by looking at genetics and epigenetics to help direct individualized medical treatments for cancer and other illnesses.
We provide innovative biomedical and genetic testing through liquid biopsies to support personalized medicine and cancer immunotherapy. We perform genetic and epigenetic testing, expression profiling, cell-free DNA (cfDNA), and circulating tumor cells (CTC) as part of assessing cancer risk, cancer progression and overall monitoring. We conduct cytokine assays to view and monitor the progress of immunotherapy, and offer genetic health risk reports.
We also provide the expertise and technology to create the most advanced biological therapies including individualized dendritic cell cancer vaccines and natural killer cell therapies, at the direction of and within the licensed cell processing facility of the Fukuro Clinic, and are constantly researching and improving on our methods to provide patients with the best treatments possible. Our number one priority is to provide safe and effective treatments with minimal to no side effects.
We believe that ImmunoGenex is at the forefront of this technology and we will continue to move forwards as we further our research, develop new tools and treatments, and continue to grow.